

October 5, 1970

Dr. Stephen Bernstein  
Psychopharmacology Research Branch  
National Institute of Mental Health  
5454 Wisconsin  
Chevy Chase, Maryland 20015

Dear Steve,

Separately I am sending you a dozen each of recent reprints published with the support of MH-13358, as requested in the recent ECDEU Intercom.

Incidentally, you are to be congratulated on the first two issues. My staff and I read these issues with much interest.

There is one problem, recently brought to my attention that may be discussed by the ECDEU investigators with some profit, that of the compensation of subjects injured in our studies. I am enclosing a thoughtful article from a recent issue of Science. This has become particularly important as more investigators are assessing drugs in normal subjects (B. Goldstein, T. Iti., L. Goldstein and C. Pfeiffer, myself); in ambulatory outpatients (Rickels, Wheatley, Engelhardt); and in children and adolescents (Engelhardt, Connors, Fish, Simeon) - populations which provide unique ethical considerations. The issue was once discussed at length by the Clinical Committee (1961 or 1962) but no action was taken. Perhaps, a review is indicated at this time.

My best regards.

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry

MF:kt

encs: Havighurst: Science, 10 July 70